Aarti Drugs Limited has submitted a regulatory disclosure to both BSE Limited and National Stock Exchange of India Limited regarding an upcoming board meeting. The disclosure is made pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Board of Directors meeting is scheduled for Tuesday, November 3, 2026. The primary agenda of this meeting is to consider, approve, and take on record the Audited Financial Results for the quarter and half year ended September 30, 2026.
In continuation of the company's earlier intimation dated September 29, 2026, the trading window for the company's securities will remain closed until 48 hours after the declaration of these financial results. This information is also available on the company's website at www.aartidrugs.com.
The communication is digitally signed by Rushikesh Deole, who is identified as the Company Secretary & Compliance Officer (ICSI Membership No. F12932).